Starten Sie Ihre Suche...


Durch die Nutzung unserer Webseite erklären Sie sich damit einverstanden, dass wir Cookies verwenden. Weitere Informationen

Preclinical evaluation of an anti-lL-36R antibody treatment as a new therapy approach for IL-17A-NFKBIZ-driven psoriasis

Laufzeit: 01.01.2022 - 31.12.2023

imported

Kurzfassung


In order to investigate if an anti-lL-36R antibody can be used for the treatment of IL-17A-driven of IL- 17 A-driven psoriatic syndromes, we want to perform the following experiments
1. Anti-lL-36R antibody treatment of mice with an established IMQ-induced psoriasis-like skin inflammation.
2. Anti-lL-36R antibody treatment of Kl4-IL17Aind Nfkbizt1/+ mice before disease onset (prophylactic protocol).
3.Anti-lL-36R antibody treatment of K14-IL17Aind Nfkbiz111+ mice after the development...
In order to investigate if an anti-lL-36R antibody can be used for the treatment of IL-17A-driven of IL- 17 A-driven psoriatic syndromes, we want to perform the following experiments
1. Anti-lL-36R antibody treatment of mice with an established IMQ-induced psoriasis-like skin inflammation.
2. Anti-lL-36R antibody treatment of Kl4-IL17Aind Nfkbizt1/+ mice before disease onset (prophylactic protocol).
3.Anti-lL-36R antibody treatment of K14-IL17Aind Nfkbiz111+ mice after the development of psoriatic lesions (therapeutic protocol).
» weiterlesen» einklappen

Beteiligte Einrichtungen